RT Conference Proceedings
T1 REAL LIFE DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. UTILITY OF THE REDOSER TOOL
A1 Arija, S. Manrique
A1 Cabezas-Lucena, A. M.
A1 Godoy-Navarrete, F.
A1 Morales-Aguila, M.
A1 Redondo, R.
A1 Mena-Vazquez, N.
K1 British society
K1 Arthritis
K1 Risk
K1 Arthritis, Psoriatic
K1 Drug Tapering
AB Background: The long-term use of standard dosing of TNFi therapy is costly and not without side effects, including infections, tuberculosis and potential malignancies(1,2,). Hence, we undertook this study to determine whether dose reduction of TNFi therapy may be possible in a realworld setting and if REDOSER tool(3) is an appropriateness criteria for reducing the dose of BT. Objectives: Describe the percentage of patients with inflammatory rheumatic diseases (IRD) who continue with dose reduction of biological therapy (BT). Evaluate relapse in clinical practice after 2 years of follow-up. Identify factors associated with relapse. Methods: Retrospective observational study. Patients with axial spondyloarthritis (axial SpA), psoriatic arthritis (PSA) and rheumatoid arthritis (RA) in BT dose reduction. Inclusion criteria: Axial SpA according to ASAS criteria, APS according to CASPAR criteria and RA according to ACR2010 criteria, who have started reducing the dose of BT treatment between 2009-2019 at the Hospital Regional Universitario de Málaga, Spain. Protocol: patients with TB are followed prospectively in a monographic consultation with a pre-established protocol. The day of dose reduction = baseline visit (v0).
PB BMJ Group
SN 0003-4967
YR 2022
FD 2022-06-01
LK http://hdl.handle.net/10668/20053
UL http://hdl.handle.net/10668/20053
LA en
NO Arija, S. M., Cabezas-Lucena, A. M., Godoy-Navarrete, F., Morales-Águila, M., Redondo, R., & Mena-Vázquez, N. (2022). AB0753 REAL LIFE DOSE REDUCTION OF BIOLOGICAL THERAPY IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES. UTILITY OF THE REDOSER TOOL. Annals Of The Rheumatic Diseases, 81(Suppl 1), 1502.1-1502
DS RISalud
RD Oct 16, 2025